Non-Hodgkin Lymphoma | Specialty

Risk Classification and Assessment in Follicular Lymphoma

July 24th 2018

Follicular Lymphoma Diagnostic Workup

July 24th 2018

Ibrutinib/Rituximab Emerges as New Standard in Waldenstrom Macroglobulinemia

July 23rd 2018

Results from the phase III iNNOVATE trial established the combination of ibrutinib plus rituximab as the new standard of care in Waldenström macroglobulinemia.

Dr. Vose Discusses the Importance of Genomic Analysis in NHL

July 18th 2018

Julie M. Vose, MD, MBA, professor, internal medicine, chief, Division of Oncology & Hematology, University of Nebraska Medical Center, discusses the importance of genomic analysis in patients with non-Hodgkin lymphoma.

Navigating the Toxicities of Novel-Novel Combinations in Lymphoma

July 18th 2018

Combinations of novel drugs in lymphomas have the potential to overcome resistance to therapy but come with sometimes unexpected adverse events that demand careful monitoring.

CAR T-cell Therapies Offer Hope for DLBCL

July 15th 2018

Chimeric antigen receptor T-cell therapies have quickly moved from early phase clinical trials to FDA approval for diffuse large B-cell lymphoma, with research now exploring ways to shift these agents earlier in the treatment paradigm.

Frontline Ibrutinib Plus R-CHOP Misses Primary Endpoint in Phase III DLBCL Trial

July 11th 2018

Combining ibrutinib with standard R-CHOP did not improve event-free survival versus R-CHOP alone in the first-line setting for patients with diffuse large B-cell lymphoma.

Dr. Flinn on CAR T-Cell Therapy in Non-Hodgkin Lymphoma

July 11th 2018

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses chimeric antigen receptor (CAR) T-cell therapy in non-Hodgkin lymphoma (NHL).

PFS Valid Surrogate Endpoint for Overall Survival in Frontline DLBCL

July 11th 2018

Progression-free survival appears to be a surrogate endpoint for overall survival in patients undergoing first-line treatment for diffuse large B-cell lymphoma, according to results from a large pooled analysis.

Dr. Abramson Discusses Lisocabtagene Maraleucel in NHL

July 10th 2018

Jeremy S. Abramson, MD, clinical director, Center for Lymphoma, Massachusetts General Hospital, discusses lisocabtagene maraleucel (JCAR017; liso-cel) as a treatment for patients with non-Hodgkin lymphoma.

Pixantrone Falls Short in Phase III B-Cell NHL Trial

July 9th 2018

Combining pixantrone (Pixuvri) with rituximab (Rituxan) failed to improve progression-free survival compared with gemcitabine plus rituximab in patients with aggressive B-cell non-Hodgkin lymphoma.

Axicabtagene Ciloleucel Approaches EU Approval for DLBCL, PMBCL

June 29th 2018

The European Medicines Agency’s CHMP has recommended approval of axicabtagene ciloleucel (axi-cel; Yescarta) as a treatment for adult patients with relapsed/refractory diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma.

Tisagenlecleucel Nears European Approval for DLBCL, ALL

June 29th 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of tisagenlecleucel for the treatment of either adult patients with diffuse large B-cell lymphoma that is relapsed or refractory after 2 or more lines of systemic therapy, or patients up to 25 years of age with B-cell acute lymphoblastic leukemia that is refractory, in relapse posttransplant, or in second or later relapse.

FDA Grants Ibrutinib/Rituximab Priority Review for Waldenstrom Macroglobulinemia

June 25th 2018

The FDA has granted a priority review to a supplemental new drug application for ibrutinib for use in combination with rituximab as a treatment option across all lines of therapy for patients with Waldenström macroglobulinemia.

Expert Discusses Venetoclax Potential in MCL

June 22nd 2018

Toby Eyre, MBChB, MRCP, discusses the results of the phase I study with venetoclax in patients with poor-risk relapsed/refractory mantle cell lymphoma.

Novel Targeted Antibody-Drug Conjugates in Non-Hodgkin Lymphoma

June 18th 2018

Antibody-drug conjugates represent a targeted class of agents with an improved therapeutic index over traditional chemotherapy in the treatment of non-Hodgkin lymphoma.

Tisagenlecleucel Demonstrates Durable Response Beyond 1 Year in DLBCL

June 17th 2018

At a median follow-up of 14.1 months, the chimeric antigen receptor T-cell therapy tisagenlecleucel achieved an objective response rate of 52% in adult patients with relapsed/refractory diffuse large B-cell lymphoma.

Polatuzumab Vedotin Plus BR Demonstrates Higher PET-CR in DLBCL

June 16th 2018

The addition of polatuzumab vedotin to bendamustine and rituximab induced a higher rate of complete responses by PET scan compared with BR alone in patients with relapsed/refractory diffuse large B-cell lymphoma.

Obinutuzumab/Chlorambucil Solidified as Frontline CLL Option

June 15th 2018

The combination of obinutuzumab and chlorambucil reduced the risk of death by 24% versus rituximab plus chlorambucil in treatment-naïve patients with chronic lymphocytic leukemia with comorbidities.

Flinn Highlights Emerging Combos in Non-Hodgkin Lymphoma

June 15th 2018

Ian Flinn, MD, PhD, discusses the activity and tolerability of 5F9 with rituximab in relapsed/refractory non-Hodgkin lymphoma, as well as intriguing findings with ibrutinib/venetoclax in frontline chronic lymphocytic leukemia.